EGFR and non-small cell lung carcinoma: A preplanned analysis of the phase 3 FLAURA study investigated osimertinib in comparison with first-generation TKIs as un upfront treatment in metastatic Exon19 deleted/L858R EGFR-mutated NSCLC, showed that four out of five patients had a complete radiological response of LM.